Julian Adams, Gamida Cell CEO
As sirens blare on biotech public markets, small cell therapy player Gamida plans to axe 10% of staff
With biotech on a major slowdown and funding dried up, small biotechs are having to scramble to cover their bottom lines. In the case of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
